Publication | Closed Access

Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)

Metastatic Breast CancerOncologyBreast OncologyMedicinePhase Iii TrialClinical TrialsFront-line ChemotherapyBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyCancer ChemotherapyChemotherapy